Skip to main content

Dr. Richard T. Frederick, M.D.

Gastroenterology (Gastroenterology Physician)

  • Medicare participating

At a glance

Medical school
New York Medical College (1998)
Years since graduation
28
In the NPI registry since
2006
Medicare patients seen, 2024
461

Licensed in California since 2000, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1998Medical school: New York Medical College
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gastroenterology Physician primary
    CA license A71441 (first issued 2000; current)
  • Hepatology Physician
    CA license A71441 (first issued 2000; current)
  • Internal Medicine Physician
    CA license A71441 (first issued 2000; current)
  • Transplant Hepatology Physician
    CA license A71441 (first issued 2000; current)
  • Transplant Surgery Physician
    CA license A71441 (first issued 2000; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gastroenterology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
461
Services billed
1,066
Patients’ average age
69
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes379267
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes23863
Established patient office or other outpatient visit, 30-39 minutes10392
Critical care, first 30-74 minutes5613
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes4339
New patient office or other outpatient visit, 60-74 minutes3737
Measurement of liver stiffness2626
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2314
New patient office or other outpatient visit, 45-59 minutes1515

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 35 payments worth $45,689 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$39,307
Consulting Fee$3,240
Travel and Lodging$1,621
Food and Beverage$1,522

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 11, 2025Madrigal Pharmaceuticals
Feb 11, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Apr 14, 2025Madrigal Pharmaceuticals
Apr 14, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Aug 18, 2025Madrigal Pharmaceuticals
Aug 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Mar 10, 2025Madrigal Pharmaceuticals
Mar 10, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jun 26, 2025Madrigal Pharmaceuticals
Jun 26, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 30, 2025Madrigal Pharmaceuticals
Jul 30, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Aug 12, 2025Madrigal Pharmaceuticals
Aug 12, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Sep 11, 2025Madrigal Pharmaceuticals
Sep 11, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Oct 29, 2025Madrigal Pharmaceuticals
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Oct 29, 2025Mallinckrodt Hospital Products Inc.
Oct 29, 2025
Consulting Fee
TERLIVAZ · CRITICAL CARE
$2,790
All 20 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Oct 29, 2025Madrigal Pharmaceuticals
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Oct 29, 2025Mallinckrodt Hospital Products Inc.
Oct 29, 2025
Consulting Fee
TERLIVAZ · CRITICAL CARE
$2,790
Oct 29, 2025Madrigal Pharmaceuticals
Oct 29, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to BURLINGAME, CA
$141
Sep 11, 2025Madrigal Pharmaceuticals
Sep 11, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Sep 11, 2025Madrigal Pharmaceuticals
Sep 11, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to BERKELEY, CA
$131
Aug 18, 2025Madrigal Pharmaceuticals
Aug 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Aug 18, 2025Madrigal Pharmaceuticals
Aug 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to CHICO, CA
$16.93
Aug 12, 2025Madrigal Pharmaceuticals
Aug 12, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Aug 12, 2025Madrigal Pharmaceuticals
Aug 12, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to OAKLAND, CA
$122
Jul 31, 2025Madrigal Pharmaceuticals
Jul 31, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$1,234
Jul 30, 2025Madrigal Pharmaceuticals
Jul 30, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 30, 2025Madrigal Pharmaceuticals
Jul 30, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to LAFAYETTE, CA
$185
Jun 26, 2025Madrigal Pharmaceuticals
Jun 26, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jun 26, 2025Madrigal Pharmaceuticals
Jun 26, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to BURLINGAME, CA
$116
Apr 14, 2025Madrigal Pharmaceuticals
Apr 14, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Mar 10, 2025Madrigal Pharmaceuticals
Mar 10, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Feb 11, 2025Madrigal Pharmaceuticals
Feb 11, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Feb 11, 2025Madrigal Pharmaceuticals
Feb 11, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to REDDING, CA · in-kind
$810
Feb 10, 2025Cipla USA Inc.
Feb 10, 2025
Consulting Fee$450
Jan 29, 2025Madrigal Pharmaceuticals
Jan 29, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to MIAMI, FL
$98.82

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $106,885 in research payments for these studies, mostly to the institutions running them.

  • A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and …
    AstraZeneca Pharmaceuticals LP
  • A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
    Bausch Health US, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in San Francisco

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 26, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1720009160. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.